NEWELL BRANDS INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NEWELL BRANDS INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $14.74B | Mar 1, 2018 |
| FY2017 | Dec 31, 2016 | $13.26B | Mar 1, 2018 |
| FY2017 | Dec 31, 2015 | $5.92B | Mar 1, 2018 |
| FY2016 | Dec 31, 2014 | $5.73B | Mar 1, 2017 |
| FY2015 | Dec 31, 2013 | $5.61B | Feb 29, 2016 |
| FY2014 | Dec 31, 2012 | $5.51B | Mar 2, 2015 |
| FY2013 | Dec 31, 2011 | $5.51B | Mar 3, 2014 |
| FY2012 | Dec 31, 2010 | $5.66B | Mar 1, 2013 |
| FY2011 | Dec 31, 2009 | $5.48B | Feb 29, 2012 |
| FY2010 | Dec 31, 2008 | $6.47B | Mar 1, 2011 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.20B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $7.58B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $8.13B | Feb 13, 2026 |
| FY2022 | Dec 31, 2022 | $2.29B | Feb 15, 2023 |
| FY2022 | Sep 30, 2022 | $2.25B | Feb 15, 2023 |
| FY2022 | Jun 30, 2022 | $2.53B | Feb 15, 2023 |
| FY2022 | Mar 31, 2022 | $2.39B | Feb 15, 2023 |
| FY2022 | Dec 31, 2021 | $2.81B | Feb 15, 2023 |
| FY2022 | Sep 30, 2021 | $2.79B | Feb 15, 2023 |
| FY2022 | Jun 30, 2021 | $2.71B | Feb 15, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.43B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $2.55B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $2.35B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $2.83B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $3.36B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $3.08B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $3.22B | Feb 14, 2022 |
| FY2020 | Dec 31, 2018 | $3.52B | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $3.81B | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $2.97B | Mar 4, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($285.00M) | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | ($216.00M) | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | ($388.00M) | Feb 13, 2026 |
| FY2022 | Dec 31, 2022 | ($249.00M) | Feb 15, 2023 |
| FY2022 | Sep 30, 2022 | $19.00M | Feb 15, 2023 |
| FY2022 | Jun 30, 2022 | $199.00M | Feb 15, 2023 |
| FY2022 | Mar 31, 2022 | $228.00M | Feb 15, 2023 |
| FY2022 | Dec 31, 2021 | $98.00M | Feb 15, 2023 |
| FY2022 | Sep 30, 2021 | $215.00M | Feb 15, 2023 |
| FY2022 | Jun 30, 2021 | $216.00M | Feb 15, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $39.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $67.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | ($85.00M) | Feb 13, 2026 |
| FY2022 | Dec 31, 2022 | ($273.00M) | Feb 15, 2023 |
| FY2022 | Sep 30, 2022 | $40.00M | Feb 15, 2023 |
| FY2022 | Jun 30, 2022 | $328.00M | Feb 15, 2023 |
| FY2022 | Mar 31, 2022 | $217.00M | Feb 15, 2023 |
| FY2022 | Dec 31, 2021 | $170.00M | Feb 15, 2023 |
| FY2022 | Sep 30, 2021 | $316.00M | Feb 15, 2023 |
| FY2022 | Jun 30, 2021 | $329.00M | Feb 15, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $114.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $123.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $117.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $140.00M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $153.00M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $144.00M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $149.00M | Feb 14, 2022 |
| FY2020 | Dec 31, 2018 | $151.00M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $175.00M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $147.00M | Mar 4, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.99B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $2.08B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $2.00B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $2.03B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $2.27B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $2.19B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $2.45B | Feb 14, 2022 |
| FY2020 | Dec 31, 2018 | $2.65B | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $2.92B | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $2.61B | Mar 4, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $264.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $496.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $930.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | ($272.00M) | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $884.00M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $1.43B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $1.04B | Feb 14, 2022 |
| FY2020 | Dec 31, 2018 | $680.00M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $966.20M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $1.84B | Mar 4, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.72B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $11.00B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $12.16B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $13.26B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $14.27B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $14.70B | Feb 14, 2022 |
| FY2020 | Dec 31, 2019 | $15.64B | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $17.72B | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $33.14B | Mar 4, 2019 |
| FY2017 | Dec 31, 2016 | $33.84B | Mar 1, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.32B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $8.25B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $9.05B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $9.74B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $10.11B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $10.80B | Feb 14, 2022 |
| FY2020 | Dec 31, 2019 | $10.65B | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $12.47B | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $18.95B | Mar 4, 2019 |
| FY2017 | Dec 31, 2016 | $22.45B | Mar 1, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.39B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $2.75B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $3.11B | Feb 13, 2026 |
| FY2025 | Dec 31, 2022 | $3.52B | Feb 13, 2026 |
| FY2024 | Dec 31, 2021 | $4.16B | Feb 14, 2025 |
| FY2021 | Dec 31, 2020 | $3.87B | Feb 14, 2022 |
| FY2020 | Dec 31, 2019 | $4.96B | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $5.22B | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $14.14B | Mar 4, 2019 |
| FY2017 | Dec 31, 2016 | $11.35B | Mar 1, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.10B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $3.04B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $3.07B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $3.30B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $3.50B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $3.55B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $3.71B | Feb 14, 2022 |
| FY2020 | Dec 31, 2018 | $3.87B | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $7.80B | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $6.52B | Mar 4, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.23B) | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | ($2.94B) | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | ($2.73B) | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | ($2.34B) | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | ($2.54B) | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | ($3.17B) | Feb 14, 2022 |
| FY2020 | Dec 31, 2019 | ($2.40B) | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | ($2.51B) | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $4.61B | Mar 4, 2019 |
| FY2017 | Dec 31, 2016 | $2.29B | Mar 1, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $203.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $198.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $332.00M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $287.00M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $440.00M | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $981.00M | Feb 14, 2022 |
| FY2020 | Dec 31, 2019 | $349.00M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $495.70M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $485.70M | Mar 4, 2019 |
| FY2018 | Dec 31, 2016 | $587.50M | Mar 4, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $11.89B | Mar 1, 2017 |
| FY2016 | Dec 31, 2015 | $3.06B | Mar 1, 2017 |
| FY2015 | Dec 31, 2014 | $2.48B | Feb 29, 2016 |
| FY2014 | Dec 31, 2013 | $1.84B | Mar 2, 2015 |
| FY2013 | Dec 31, 2012 | $1.92B | Mar 3, 2014 |
| FY2012 | Dec 31, 2011 | $2.18B | Mar 1, 2013 |
| FY2011 | Dec 31, 2010 | $2.37B | Feb 29, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 13, 2026 |
| FY2022 | Dec 31, 2022 | 0 | Feb 15, 2023 |
| FY2022 | Sep 30, 2022 | 0 | Feb 15, 2023 |
| FY2022 | Jun 30, 2022 | 0 | Feb 15, 2023 |
| FY2022 | Mar 31, 2022 | 0 | Feb 15, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Feb 15, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Feb 15, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Feb 15, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 13, 2026 |
| FY2022 | Dec 31, 2022 | 0 | Feb 15, 2023 |
| FY2022 | Sep 30, 2022 | 0 | Feb 15, 2023 |
| FY2022 | Jun 30, 2022 | 0 | Feb 15, 2023 |
| FY2022 | Mar 31, 2022 | 0 | Feb 15, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Feb 15, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Feb 15, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Feb 15, 2023 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $120.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $118.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $184.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $385.00M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $394.00M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $392.00M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $391.00M | Feb 14, 2022 |
| FY2020 | Dec 31, 2018 | $435.00M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $428.60M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $328.60M | Mar 4, 2019 |